Morrison Foerster advised Celadon Partners and GeneFab, while Cooley and Goodwin Procter advised Senti Biosciences. Senti Biosciences, Inc. (Nasdaq: SNTI) and Celadon Partners, LLC announced a transaction...
You must be a Standard 1 Year member to access this content.
Cooley advised SCYNEXIS on the deal. SCYNEXIS announced its exclusive license agreement with GSK for Brexafemme. The exclusive license agreement gives GSK rights to commercialize SCYNEXIS’ ibrexafungerp...
You must be a Standard 1 Year member to access this content.
Cooley advised Tmunity on the deal. Tmunity, a clinical-stage biotechnology company, announced its agreement to sell to Kite, a global biopharmaceutical company. The acquisition will provide...
You must be a Standard 1 Year member to access this content.
Cooley advised Poseida Therapeutics on the deal. Poseida Therapeutics, a clinical-stage biopharmaceutical company, announced its strategic collaboration and license agreement with Roche. The agreement will leverage Poseida’s...
You must be a Standard 1 Year member to access this content.
Latham & Watkins Advises the Underwriters in the offering while Cooley LLP represented Lyell Immunopharma. Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company...
You must be a Standard 1 Year member to access this content.
